Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its subsidiary in India, Eisai Pharmaceuticals India Pvt. Ltd. (EIL), has received the Quality Excellence Award for Best Healthcare Industry for the year 2015 from the World Quality Congress.

EIL is Eisai’s subsidiary in India and is responsible for process research, manufacturing and sales of pharmaceutical products. EIL conducts API (active pharmaceutical ingredient) process research as well as manufacturing of API and oral solid dose products at the “Eisai Knowledge Center India,” located in southern India at Visakhapatnam (Vizag), Andhra Pradesh, and has a sales office located in Mumbai. Eisai first commenced operation at the Vizag site in 2009, aiming to supply pharmaceuticals and APIs worldwide, with technology transferred from Japan in order to apply Eisai’s unified global quality assurance standards at the plant. The Vizag plant, located within the Eisai Knowledge Center, currently supplies diethylcarbamazine citrate (DEC) tablets for treatment of lymphatic filariasis to the World Health Organization (WHO) free of charge, and Aricept®, a treatment for Alzheimer’s disease and dementia with Lewy bodies, among other products.

Administered by the World Quality Congress, an international forum to promote quality improvement, the aim of the Quality Excellence award is to recognize, motivate and acknowledge excellence in Quality Management and leadership, and is given to organizations in recognition of achieving excellence in areas such as quality improvement through teamwork, adoption of international standards and regulations as well as having the agility and flexibility to meet patient needs. The Vizag plant received this award in the Best Healthcare Industry category.

EIL was selected for this award based on its quality management system, which conforms to the highest standards enabling the consistent and stable supply of products to the strict Japan market without any quality issues and is continuously improved according to global regulatory expectations. Other reasons given included obtaining pre-qualification certification in record time from WHO for DEC tablets as well as being the industry benchmark for organization building and talent management initiatives.

In addition, the Eisai Knowledge Center India has received a number of awards as outlined below:
-Received the International Society for Pharmaceutical Engineering’s “Facility of the Year Award” (FOYA) in 2012 for project execution. EIL was the first company in India to receive the award.
-Received the “Leadership and Excellence Award in Environment Health & Safety” determined by the Confederation of Indian Industry (CII) for three consecutive years since
2012.
- Received recognition in the “India Pharma Awards” in 2013 by UBM.
- Received an “Honor Certificate for Green Field Manufacturing” from the Pharmaceuticals Export Promotion Council in India.
- Received the “National Award for Excellence in the Healthcare Sector” in 2015 for the best R&D in pharmaceuticals.

Eisai will further promote its hhc (human health care) philosophy and will continue to contribute to increasing the benefits of patients and their families around the globe by ensuring a stable supply of high quality pharmaceutical products that meet the various needs of different countries and markets around the world.

The awards ceremony was held at the Hotel Taj Lands’ End in Mumbai on July 23

(From left to right) Dr. Seth Adjei Baah from the Ghana Chamber of Commerce and Industry, Dr. Sanjit Lamba from EIL and Mr. Madan Mohan Reddy